Modality
ASO
MOA
TROP-2 ADC
Target
GLP-1R
Pathway
Amyloid
ACCALL
Development Pipeline
Preclinical
Dec 2023
→ Oct 2031
PreclinicalCurrent
NCT07264876
2,648 pts·ALL
2025-01→2031-10·Completed
NCT04125755
1,038 pts·ACC
2023-12→2030-09·Completed
3,686 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2030-09-144.5y awayInterim· ACC
2031-10-125.5y awayInterim· ALL
Trial Timeline
2024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
Preclinical
Complet…
Preclinical
Complet…
Catalysts
Interim
2030-09-14 · 4.5y away
ACC
Interim
2031-10-12 · 5.5y away
ALL
Completed|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07264876 | Preclinical | ALL | Completed | 2648 | PASI75 |
| NCT04125755 | Preclinical | ACC | Completed | 1038 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| Tirzepatide | Eli Lilly | Approved | GLP-1R | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| Mavuglumide | Bayer | Approved | GLP-1R | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| Bemarelsin | Daiichi Sankyo | Preclinical | GLP-1R | |
| Bemazumab | Regeneron | Phase 1 | VEGF |